Virothera presented at the International Society of Vaccines in Lausanne, Switzerland in October, 2023 and follows up at the Biotech Showcase in San Francisco, USA in January, 2024.
‘Advancing next generation immune therapeutic DNA medicines for all.’
Cambridge, UK December 28, 2023 – Virothera presented initial results on its highly effective therapeutic DNA vaccine for herpes simplex virus 2 (HSV-2) at the International Society of Vaccines (ISV) in October in Lausanne, Switzerland. Virothera’s CEO Founder, Dr Ursula Gompels, will attend Biotech Showcase in January 2024 and deliver updates on Virothera’s pipeline assets and technology platform.
Biotech Showcase takes place January 8-11, at the Hilton Union Square in San Francisco,California, USA and is one of 2024’s foremost events within the biotechnology industry.
Virothera’s CEO will be introducing the company’s next generation proprietary platform technologies for immune regulation, which are applicable across infectious disease, immune oncology and autoimmune conditions. Our lead candidate, which applies these technologies, is a breakthrough therapeutic DNA vaccine for HSV-2. It has shown much promise for clinical evaluation in preclinical in vivo trials, which were performed under preclinical services programs supported by the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH*.
Virothera’s lead candidate has demonstrated 100% preclinical protection from acute disease(1), 73% therapeutic protection overall in those animals infected with HSV-2, which increased to 100% after two months. In addition, it reduces disease as well as virus secretion, a WHO preferred product characteristic(2,3).
CEO Dr Gompels says, “These results are exciting as not only has our lead candidate for HSV-2 performed very well in the leading preclinical model in vivo, but our breakthrough cytokine based approach targets human regulatory T cells, T-Regs, and should work even better in people. Our immunomodulator can inhibit T-Regs, thereby enhancing the immune response. We are now refining dosing in preparation for transition to clinical evaluation. It was an honour to present our company’s results at the ISV, the premier vaccine congress, and I look forward to updating on this in San Francisco at Biotech Showcase, the prestigious international Biotechnology conference headlining the new year.”
CEO of Demy-Colton, Sara Demy adds, “We are delighted that Virothera will be joining us in San Francisco at Biotech Showcase this year, Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
About Biotech Showcase
Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 16th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry. Find out more at https://informaconnect.com/biotech-showcase
About Virothera
Virothera aims to bring novel gene immune therapeutics to all. Virothera’s technologies regulate protective immunity by new controls to our chemokine system, immune cell conductors recruiting or regulating effective immunity. These are leading to development of novel therapeutics. Its lead candidate is a novel gene based HSV-2 preventative and therapeutic vaccine now approaching the clinic. This is followed by similarly chemokine sensitive targets, an inhibitor of metastatic TN breast cancer and an immune regulator for Rheumatoid Arthritis. Find out more at www.virothera.co.uk
Contacts
Dr Ursula Gompels, CEO
info@virothera.co.uk
Virothera Ltd
Milner Therapeutics Institute
Jeffrey Cheah Biomedical Centre
Cambridge
UK
References
(1) Gompels, U.; Bravo, F.; Briggs, S.; Ameri, S.; Cardin, R.; Bernstein, D. (2022) Immunisation Using Novel DNA Vaccine Encoding Virus Membrane Fusion Complex and Chemokine Genes Shows High Protection from HSV-2. Viruses, 14(11), 2317; https://doi.org/10.3390/v14112317. https://www.mdpi.com/1999-4915/14/11/2317
(2) Gompels, U.; Bravo, F.; Briggs, S.; Ameri, S.; Cardin, R.; Bernstein, D. (2023) Next generation DNA vaccine shows highly effective immunetherapeutic platform with unique chemokine and stabilised membrane entry complex genes immunisation delivering protection from acute and recurrent HSV-2. International Society of Vaccines Congress, Lausanne, Switzerland, P35.
(3) https://www.who.int/publications/i/item/9789241515580
* Supported by Virothera Ltd & Preclinical services programs NIAID, NIH, USA; NIH contract HHSN272201700017I, Task Order HHSN27200003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.